Abciximab-Induced Delayed Profound Thrombocytopaenia
No commercial use is permitted unless otherwise expressly granted. Abciximab, the first approved glycoprotein (GP IIb/IIIa) inhibitor, is being widely used during acute coronary syndromes and offers the promising approach to antithrombotic therapy. We present a case of a young woman who initially received abciximab infusion for undergoing percutaneous coronary intervention of left anterior descending artery and was eventually diagnosed with abciximab-induced delayed thrombocytopaenia. This case outlines the importance of close follow-up of these patients to prevent serious adverse events.
Jbara, Manar; Bhogal, Sukhdeep; Bajaj, Kailash; and Chhabra, Lovely. 2017. Abciximab-Induced Delayed Profound Thrombocytopaenia. BMJ Case Reports. Vol.2017 https://doi.org/10.1136/bcr-2017-219379 PMID: 28576909